Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs (opens original article in a new tab)

Derm-Biome's DB-006 showed superior efficacy in preclinical studies for atopic dermatitis, reducing key symptoms and outperforming existing treatments.

• DB-006 reduced itch, inflammation, and IgE levels in preclinical atopic dermatitis study
• DB-006 outperformed ZORYVE and VTAMA in reducing symptoms
• DB-006 has antimicrobial activity against Staphylococcus aureus